- Home
- FTDR vs GH Comparison
FTDR vs GH Comparison
Compare FTDR & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTDR
- GH
- Stock Information
- Founded
- FTDR 1971
- GH 2011
- Country
- FTDR United States
- GH United States
- Employees
- FTDR N/A
- GH N/A
- Industry
- FTDR Diversified Commercial Services
- GH Medical Specialities
- Sector
- FTDR Finance
- GH Health Care
- Exchange
- FTDR Nasdaq
- GH Nasdaq
- Market Cap
- FTDR 4.2B
- GH 4.9B
- IPO Year
- FTDR 2018
- GH 2018
- Fundamental
- Price
- FTDR $58.48
- GH $49.14
- Analyst Decision
- FTDR Hold
- GH Strong Buy
- Analyst Count
- FTDR 4
- GH 20
- Target Price
- FTDR $54.00
- GH $54.35
- AVG Volume (30 Days)
- FTDR 531.9K
- GH 2.2M
- Earning Date
- FTDR 07-31-2025
- GH 08-06-2025
- Dividend Yield
- FTDR N/A
- GH N/A
- EPS Growth
- FTDR 34.69
- GH N/A
- EPS
- FTDR 3.08
- GH N/A
- Revenue
- FTDR $1,891,000,000.00
- GH $773,996,000.00
- Revenue This Year
- FTDR $12.86
- GH $23.14
- Revenue Next Year
- FTDR $6.54
- GH $21.42
- P/E Ratio
- FTDR $19.01
- GH N/A
- Revenue Growth
- FTDR 5.58
- GH 28.20
- 52 Week Low
- FTDR $32.95
- GH $20.14
- 52 Week High
- FTDR $63.49
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- FTDR 65.32
- GH 62.17
- Support Level
- FTDR $56.48
- GH $48.00
- Resistance Level
- FTDR $57.55
- GH $51.71
- Average True Range (ATR)
- FTDR 1.09
- GH 2.67
- MACD
- FTDR -0.31
- GH 0.39
- Stochastic Oscillator
- FTDR 83.39
- GH 78.60
About FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.